/
Other
Weight Loss
26
Pipeline Programs↗
36
Active Trials↗
32
Companies Involved↗
Weight loss is an emerging landscape with 26 programs across 32 companies. The most active players are AstraZeneca, Novo Nordisk, Gan & Lee Pharmaceuticals.. 9 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical10
Phase 11
Phase 26
Phase 39
Approved
No programs
Analysis
Modality Breakdown
96%
Small molecule
24 of 25 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 100% of 26 pipeline programs.
Analysis
Trial Status
158
clinical trials
Completed82 · 52%
Terminated21 · 13%
Recruiting16 · 10%
Unknown status12 · 8%
Active, not recruiting9 · 6%
Not yet recruiting9 · 6%
Other9 · 6%
Clinical Trials
Trial Activity
158 trials
Randomized Control Trial of Sleeve Gastrectomy with Tirzepatide in Maximizing Weight Loss
Recruiting·—·Phase 1·NCT06734273·42 enrolled
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
Recruiting·—·Phase 4·NCT05919797·120 enrolled
Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)
Recruiting·—·Phase 3·NCT07297290·220 enrolled
Combining Chinese Medicine and Nutrition to Enhance Weight Loss After Bariatric Surgery
Recruiting·—·N/A·NCT06419764·120 enrolled
Page 1 of 11
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)